Absci Corp（ABSI）股票分析ABSIAbsci Corp

Absci Corporation is a clinical-stage biopharmaceutical company advancing therapeutics with generative design. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. It has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

Absci Corp (ABSI) is a good buy right now due to its current price of $9.18, which is below the analyst price target of $9.61, suggesting a potential upside of about 30%. Additionally, the stock has shown a significant year-to-date change of +154.29%, indicating strong investor interest and momentum. However, the main risk is its high net income loss, which was -33,210,000 USD in Q2 2026, reflecting ongoing financial challenges.